Cervical cancer vaccinations will soon be able to protect against genital warts.
From next September, the government’s nationwide vaccination programme will use Gardasil, made by Sanofi Pasteur.
Like current vaccine Cervarix, Gardasil protects against strains 16 and 18 of the human Papillomavirus (HPV) virus which cause nearly three quarters of cases of cervical cancer, but Gardasil also protects against the strains responsible for warts and lesions.
When GlaxoSmithKline’s (GSK) Ceravix was chosen in 2008, some campaigners claimed the government had made a mistake by not chosing Gardasil, with some claiming cost had played a part.
Professor David Salisbury, the government’s director of immunisation, said: “We have reflected the changes in scientific knowledge that has become available since last time.
“They are not huge changes - we still prioritise the prevention of cancer - but based on all these things, the winner is Gardasil.”
GSK did not take part in the tender process this time.